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Biventricular Pacing Among Heart Failure Patients
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Queen Mary Hospital, Hong Kong
CHAN ET AL.: Implantable Cardioverter Defibrillator Incorporated with Biventricular Pacing Among Heart
Failure Patients. Implantable cardioverter defibrillator (ICD) with biventricular pacing (BiV) is available for drugrefractory heart failure patient who has class I indication for ICD and inter-ventricular conduction delay. We studied
32 patients with mean age of 61 years (M:F=9:1) with mean ejection fraction about 30% who has underwent
implantation of implantable cardioverter defibrillator incorporated with left ventricular pacing. It showed its efficacy
in terms of improvement in functional status and ejection fraction as confirmed by echocardiogram, episodes of
cardiac related rehospitalization (p<0.05) and appropriate therapy for ventricular tachycardia among our patients
in the mean follow up period of 22 months. Permanent left ventricular pacing is achieved by pacing of the distal
branches of coronary sinus with a specially designed left ventricular (LV) lead. The optimal placement of LV lead is
identified by a satisfactory pacing threshold, ventricular sensing and late sensing of LV electrical activity in order to
optimize the resynchronization process. At the end of follow-up, all LV leads were fully functional with stable thresholds
and appropriate sensing. Eight episodes of ventricular fibrillation and 18 episodes of ventricular tachycardia were
successfully detected. The detection of ventricular arrhythmia detection was 100%. Four patients received 28
inappropriate shocks secondary to supraventricular tachycardia. Conclusion: Implantable cardioverter defibrillator
incorporated with biventricular pacing is an efficient and safe mean of providing patient with cardiac resynchronization
therapy in patient with drug refractory heart failure with interventricular conduction delay. (J HK Coll Cardiol
2003;11:50-57)
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Background
Implantable cardioverter defibrillator (ICD) has
become an important therapeutic modality for patients
who have had aborted cardiac arrest or are at risk for
life-threatening ventricular arrhythmias. Clinical trials
have already confirmed the role of ICD for patients with
sustained ventricular arrhythmias1 and have expanded
the indications to include patients with coronary artery
disease, left ventricular dysfunction with or without and
non-sustained ventricular tachycardia.2,3 Many heart
failure patients remain highly symptomatic.4 Population
morbidity and mortality still remain high.5 There is a
need to identify subgroups of patients particularly those
at high risk for newer non-pharmacological therapeutic
strategies. Previous studies have documented the
deleterious haemodynamic effects of left bundle branch
conduction delay with resultant dyssynchronous
activation of the left ventricle. Cardiac resynchronization
therapy (CRT) involves atrio-ventricular (AV) pacing
to optimize AV timing and biventricular (BiV) pacing
to synchronize right and left ventricular contractions.
It has been shown that CRT results in acute
improvement in haemodynamics,6-8 functional class, 6
minutes walking distance 9-13 and probably antiarrhythmic event in recent studies.13,14 CRT becomes
more widely applicable since the introduction of
endocardial transvenous pacing leads for left ventricular
(LV) pacing via the cannulation of branches of the
coronary sinus (CS), thus avoiding thoracotomy surgery.
The aim of this study was to report our clinical
experience and long-term outcome in patients being
implanted with ICD incorporated with CRT.

Materials and Methods
Patient Population
The study population consisted of 32 patients who
underwent successful implantation of ICD incorporated
with BiV pacing from December 1999 to June 2002.
All patients were in New York Heart Association
(NYHA) functional class II to III with optimal medical
therapy at maximal tolerated dose for congestive heart
failure and they were not dependent on inotopic support.
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All patients also have the usual indications for CRT,
namely, LV systolic dysfunction with ejection fraction
<35% on echocardiography or angiography, echographic
LV end diastolic diameter >60 mm, and intrinsic QRS
interval >140 ms. Clinical characteristics of the patients
studied are summarized in Table 1.

Implantation of ICD Incorporated with BiV
Pacing
The devices implanted in this study were
CONTAK CD (model 1832) and the newer CONTAK
Renewal model (Guidant Inc, Minneapolis, USA) and
InSync 7272 ICD (Medtronic Inc., Minneapolis, USA)
which are capable of delivering ICD therapies and CRT.
Both devices have a special five-port header for
connection of four leads, which have three pacing
electrodes (one atrial lead, one right ventricular [RV]
lead and one LV lead) and two defibrillation coil. CRT
and antitachycardia pacing (ATP) can be programmed
to the right, left or biventricular stimulation in InSync
ICD and Renewal ICD but not the earlier generation
CONTAK CD. The CONTAK CD incorporated both
RV and LV sensing in the detection algorithm while

Table 1. Patient characteristics
N=32
Age (years)
61±12 (37-83)
Male (n, %)
30 (94%)
Underlying etiology of heart failure:
Ischemic cardiomyopathy
14 (44%)
Dilated cardiomyopathy
14 (44%)
Valvular heart disease
3 (10%)
Sarcoidosis
1 (2%)
Left ventricular ejection fraction (%)
24.2±11
Follow-up (months)
22±12 (2-37)
ECG (intervals):
PR (ms)
246±22
QRS (ms)
176±20
Rhythm:
VF
8 (25%)
VT
18 (56%)
Syncope with positive induction at EPS
6 (19%)
VF=ventricular fibrillation; VT=ventricular tachycardia;
EPS=electrophysiological study
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both ventricular sensing and detection remain on the
right side lead only in InSync ICD and Renewal CD.
The LV pacing lead was inserted transvenously
via the subclavian venous route. Coronary sinus
venogram was obtained during balloon occlusion, and
specially designed LV pacing lead was inserted through
the CS into distal epicardial branch with the help of
dedicated 8Fr guiding catheters. Essentially, two
different specially designed transvenous CS pacing
leads were used. The over-the-wire design was used in
18 patients. It is a unipolar 6-French tined electrode
which contains a central lumen and an open tip through
which a 0.014 inch guidewire can be passed through
and guide the advancement of pacing lead. The second
LV pacing lead used was a pre-shaped unipolar 4.1
French passive fixation lead and was implanted in 14
patients. The atrial lead was positioned at the high right
atrium and the defibrillation lead postioned in the RV
apex respectively (Figure 1). Proper testing of the
sensing and capture thresholds of the three pacing leads

(a)

were performed. Diaphragmatic stimulation or phrenic
nerve stimulation (more commonly seen with LV lead
stimulation) were evaluated. The total implant procedure
duration, LV lead implantation time, fluoroscopic time
and defibrillation thresholds (DFT) were measured.

Clinical Evaluation and Follow-up
Prior to implantation of the device, all patients'
underwent the following assessment: New York Heart
Association (NYHA) classification and echocardiography
for determination of the LV systolic and diastolic
diameter and LV ejection fraction. After implantation,
all patients underwent optimization of CRT by
determining the optimal AV intervals for systolic LV
function using Doppler echocardiography. The device
was first programmed to a lower rate to ensure an
intrinsic sinus rate. The sensed AV delay was
programmed to 200 ms. At this setting, mitral valve
closure is delayed to the end of the A-wave. The sensed
AV interval was decreased at 20 ms intervals until the

(b)

Figure 1. Chest X-rays (PA view) of a patient with previous coronary bypass surgery implanted with ICD with biventricular
pacing performed at a) immediately after implantation and b) 1 year after. Note the significant reduction in cardiothoracic
ratio and improvement in pulmonary venous congestion.
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mitral valve Doppler signal caused truncation of the
A-wave. The optimal AV interval was programmed to
ensure that the mitral valve closure Doppler signal
coincided with or occurred shortly after the end of the
A-wave.
Patients were evaluated at outpatient clinic at
1 and 3 months, and then 6 monthly after implantation.
Arrhythmic episodes were retrieved from the device
memory and examined by the physicians. Follow up
data were acquired for up to 3 years. Cardiovascular
endpoints were defined as arrhythmic death, sudden
cardiac death, or death attributable to congestive heart
failure or myocardial infarction or other events resulting
in terminating the BiV ICD functions (for example, heart
transplantation). Hospitalizations for cardiovascular
events were defined as hospital admission secondary
to congestive heart failure, ischaemia (for example,
acute myocardial infarction and unstable angina) or
cardiac arrhythmia events. The number of cardiac
related hospitalization was compared before and after
BiV ICD implantation. The rate of re-admission was
determined by dividing the number of hospitalizations
experienced by the total number of person-years of
follow-up.

by T-wave shock induction, was 9.5±5 joules. The
procedural time was 3.8±1.2 hours and mean
fluoroscopy time was 37.1±22.4 minutes. The chronic
LV pacing thresholds, sensing and impedance were not
significantly different between the two types of leads
utilized in this study (Figure 2).

Patients' Clinical Parameters and Outcome
The ICD function and BiV pacing function were
activated in all patients after optimization of AV
intervals using doppler echocardiography. The baseline
and long-term follow up results are listed in Table 2.
There is significant improvement of mean LV ejection
fraction from 24.4% to 34% (p<0.05). There is
significant reduction in LV systolic and diastolic
dimensions. Interestingly, there was a decrease in QRS
duration but did not reach statistically significant. The
cardiac related hospitalization rate was also significantly
reduced (p<0.05). Two patients died from multi-organ
failure at 14 months and intractable heart failure at 22
months after implantation respectively. Three other
patients subsequently underwent orthotopic cardiac
transplantation for congestive heart failure. The total
event free survival without heart transplantation was
27 (84%) of 32 patients.

Statistical Analysis
Continuous data were expressed as mean±SD.
Student's t test was used to compare the results at
baseline and during their most recent follow-up. For all
tests, a p value<0.05 was considered significant.

Results
Implantation Procedure
LV lead implantation at the distal branches of
coronary sinus was successful in 91% of patients. The
reasons for unsuccessful LV lead implantation were
failure of coronary sinus branches cannulation in
2 patients and high LV capture thresholds at various
distal branches in another patient. Therefore, a total of
32 patients were entered in final analysis. The acute
mean LV pacing thresholds in those 32 patients was
1.1±0.5 V. The mean defibrillation threshold, measured
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Long Term Device Follow-up
There were 3 device related late complications
(1 wound infection and 2 LV leads dislodgement) for
which repositioning of leads was successful. Eight
patients received 19 appropriate therapies for ventricular
tachyarrhythmias (average 2.4 episodes/pt). All
ventricular tachyarrhythmias were correctly identified;
hence, sensitivity of ventricular arrhythmias detection
was 100%. Two patients initially programmed to RV
antitachycardia pacing (ATP) were programmed to BiV
ATP which was significantly more effective in
terminating ventricular tachycardia. Four patients
received 28 inappropriate shocks secondary to
supraventricular tachycardia (SVT) (n=26) and
oversensing of diaphragmatic myopotentials (n=2).
There was no inappropriate detection arising from
double counting of RV and LV signal during SVT
amongst our patients.
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(a)

(b)

(c)

Figure 2. Comparison of two types of left ventricular (LV) pacing leads with respect to their chronic
a) chronic pacing thresholds b) sensing and c) impedance. * p<0.05 when compared with implant.
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Table 2. Clinical parameters before and after ICD incorporated with BiV pacing
Baseline
176±20
6.8±1.1
5.74±1.1
24.4±11
8.6±8.2

QRS duration (ms)
LVDD (cm)
LVSD (cm)
EF (%)
Cardiac-related Rehospitalization (episodes/year)

Discussion
This report describes our clinical experience with
ICD capable of CRT in patients with severe systolic heart
failure considered at risk of malignant ventricular
tachyarrhythmias. The significant improvement in
functional class and LV dimensions together with
significant reduction in cardiac related hospital
admissions is in agreement with other recently reports.9-13
Therefore, heart failure patients with prior cardiac arrest
and marked interventricular conduction delay should
be considered as the optimal candidates to the ICD
implantation combined with BiV pacing. Furthermore,
our findings that significant QRS narrowing was not
constantly achieved with BiV pacing despite much
improved mechanical systolic response was consistent
with other studies.13
The MIRACLE-ICD (Multicenter InSync-ICD
Randomized Clinical Evaluation) was conducted in a
near-identical way to the MIRACLE trial, 8 with
implantation of ICD with CRT devices into 362 patients
with a conventional indication for ICD, LVEF <35%
and NYHA III/IV heart failure. This study showed a
marked reduction in days in hospital for heart failure
(77%; p=0.012), in the use of intravenous therapy for
heart failure (57%; p<0.001) and the outcome of death
or worsening heart failure (40%; p=0.033) during longterm follow-up. In the CONTAK-CD trial, which was
designed to assess if BiV pacing could reduce shortterm morbidity and mortality in patients with heart
failure, the primary endpoint (a composite of all-cause
mortality, hospitalization for heart failure, worsening
of heart failure requiring intervention or appropriate ICD
discharges) was reduced by 21%, which failed to
achieve statistical significance. Similar to MIRACLE-
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Post BiV ICD
146±15
6.15±0.9
5.01±1.1
34±16
3.6±6.2

P value
0.34
<0.001
<0.001
0.02
<0.0001

ICD trial, CRT was associated with important trends to
benefit, including reductions in mortality (23%),
hospitalization for heart failure (13%), worsening heart
failure events (26%), and appropriate ICD discharge
(9%). CRT was associated with a significant reduction
in echocardiographic LV dimensions, control-group
subtracted increase in peak oxygen of 1 mL/kg/min,
and improved NYHA class (33% of control group in
class I/II vs 80% of patients on CRT).
The recently completed COMPANION study
randomized patients to receive with CRT (with or
without backup defibrillator) versus optimal medical
therapy.14 The primary end-point is all-cause mortality
and all-cause hospitalization. As patients who have an
existing indication for an ICD are excluded from
COMPANION, it will effectively be assessing the use
of prophylactic ICD in patients deliberately stratified
for not being at risk of arrhythmias. This study has just
been terminated prematurely in late November 2002
because of highly significant reduction in combined all
cause mortality and all cause hospitalization in CRT
and ICD arm itself.

Incidence of Ventricular Tachyarrhythmias and
Efficacy of Therapy
Whether BiV pacing affects the incidence of
sustained ventricular tachyarrhythmias remains an
important question. Data from the beta-blocker studies
support the concept that improving heart failure reduces
sudden death, suggesting that the incidence of
ventricular arrhythmias is decreased.15 Some small
studies have shown positive effects on the incidence of
ventricular arrhythmias16,17 while recent larger studies
showed equivocal results. 18 With BiV pacing, two
distinct pacing sites are used which may enhance the
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efficacy to terminate VT by antitachycardia pacing
(ATP) as the site of stimulation may modify the ability
of a stimulated impulse to enter the re-entry circuit
and terminate VT. Kuhlkamp et al has shown that
biventricular ATP delivery was more effective than right
ventricular ATP and a trend was seen that BiV pacing
did result in fewer acceleration than right ventricular
ATP. 18 Our clinical experience demonstrated better
efficacy of ATP when delivered biventricularly in
selected patients as well.

improved ejection fraction, LV dimensions and
functional status, with reduced hospital admissions.
Implantation of ICD capable of BiV pacing is a safe
procedure in patients with severe congestive heart
failure. Ventricular tachyarrhythmia episodes in these
patients were all appropriately treated. Thus the use of
an ICD with CRT should be considered in patients with
ventricular tachycardia with evidence of intraventricular
dyssynchrony.

Inappropriate Detection of Ventricular Tachyarrhythmias
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Conclusions
In a selected group of heart failure patients with
primary indication for ICD therapy, adjunctive CRT by
implanting "an ICD combined with BiV pacing"
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